Compare Biogen Inc (BIIB) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Invesco Preferred ETF — how do they compare? Biogen Inc trades at $191.88 (market cap $28.34B), while Invesco Preferred ETF trades at $10.87. The key difference: Biogen Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | PGX | |
|---|---|---|
Market Cap | $28.34B | — |
Sector | Health | — |
52-Week High | $216.63 | $11.87 |
52-Week Low | $122.68 | $10.82 |
Enterprise Value | $30.62B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
PGX trades at $10.83, down 0.18% with a bearish technical signal from moving averages. Recent news includes the sale of the Golden Sidewalk Project to Kenorland Exploration. Financial ratios are unavailable in the current data, limiting fundamental assessment. The stock faces negative sentiment from recent analyst coverage questioning its risk-reward profile.
The outlook remains cautious given bearish technical indicators and critical analyst commentary highlighting poor returns and limited downside protection. Investment opportunities appear constrained by structural concerns, while risks include participation in market selloffs and recovery rate uncertainties in debt instruments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
